NasdaqGM - Nasdaq Real Time Price USD

KalVista Pharmaceuticals, Inc. (KALV)

11.34

-0.30

(-2.58%)

At close: May 14 at 4:00:01 PM EDT

10.82

-0.52

(-4.59%)

After hours: May 14 at 6:17:29 PM EDT

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. & SALISBURY, England, May 02, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted three newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on May 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the

Business Wire 12 days ago

KALV
-2.58%
KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

CAMBRIDGE, Mass. & SALISBURY, England, April 30, 2025--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 11:30 a.m. ET.

Business Wire 14 days ago

KALV
-2.58%
KalVista licenses commercialisation rights for HAE to Kaken in Japan

KalVista will be paid $11m upfront with the possibility of a further $11m.

Pharmaceutical Technology last month

KALV
-2.58%
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

CAMBRIDGE, Mass. & SALISBURY, England, April 08, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has licensed commercialization rights in Japan to Kaken Pharmaceutical, Co., Ltd. (JPX: 4521.T) for sebetralstat, an investigational, oral on-demand treatment for hereditary angioedema (HAE). KalVista will receive an upfront payment of $11 million, with an additional payment of up to $11 million upon achievement of

Business Wire last month

KALV
-2.58%
KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass. & SALISBURY, England, March 31, 2025--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 1:30 p.m. ET.

Business Wire last month

KALV
-2.58%
KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial

The trial aims to gather pharmacokinetic, efficacy and safety data for a period of up to 12 months.

Clinical Trials Arena last month

KALV
-2.58%
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

CAMBRIDGE, Mass. & SALISBURY, England, March 25, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of sebetralstat, an investigational, novel, oral plasma kallikrein inhibitor, in pediatric patients between the ages of two and 11 with hereditary angioedema (HAE).

Business Wire last month

KALV
-2.58%
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

CAMBRIDGE, Mass. & SALISBURY, England, March 12, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today released financial results for the third fiscal quarter ended January 31, 2025, and provided an operational update.

Business Wire 2 months ago

KALV
-2.58%
KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

CAMBRIDGE, Mass. & SALISBURY, England, March 10, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it will host a virtual event to provide an overview of the commercialization strategy, plans and progress for sebetralstat, the Company’s investigational treatment for hereditary angioedema (HAE). The event will take place on Tuesday, March 25, 2025, from 8:00 a.m. to 10:00 a.m. ET. To register, please click here.

Business Wire 2 months ago

KALV
-2.58%
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

CAMBRIDGE, Mass. & SALISBURY, England, March 03, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of novel sebetralstat data related to laryngeal hereditary angioedema (HAE) attacks and adolescents with HAE at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, CA from February 28–March 3, 2025.

Business Wire 2 months ago

KALV
-2.58%
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. & SALISBURY, England, February 24, 2025--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences:

Business Wire 2 months ago

KALV
-2.58%
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

CAMBRIDGE, Mass. & SALISBURY, England, February 21, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that six abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, CA from February 28–March 3, 2025.

Business Wire 2 months ago

KALV
-2.58%
KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

CAMBRIDGE, Mass. & SALISBURY, England, February 10, 2025--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 Annual Meeting taking place in Waimea, HI from February 9-13, 2025.

Business Wire 3 months ago

KALV
-2.58%
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

CAMBRIDGE, Mass. & SALISBURY, England, January 21, 2025--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan Drug Designation. The Company has also submitted a New Drug Application (NDA) for sebetralstat to the Agency. If approved, sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and adolescents a

Business Wire 3 months ago

KALV
-2.58%
Sector Update: Health Care Stocks Advance in Afternoon Trading

Health care stocks were rising Wednesday afternoon, with the NYSE Health Care Index adding 0.3% and

PREMIUM
MT Newswires 4 months ago

KALV
-2.58%
KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says

KalVista Pharmaceuticals' (KALV) drug candidate sebetralstat is a promising, on-demand oral treatmen

PREMIUM
MT Newswires 4 months ago

KALV
-2.58%
KalVista Appoints Jeb Ledell as Chief Operating Officer

CAMBRIDGE, Mass. & SALISBURY, England, December 16, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry.

Business Wire 4 months ago

KALV
-2.58%
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

CAMBRIDGE, Mass. & SALISBURY, England, December 05, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today released financial results for the second fiscal quarter ended October 31, 2024. The Company also provided an operational update, highlighted by the U.S. Food and Drug Administration (FDA) acceptance of a New Drug Application (NDA) for sebetralstat, a novel, investigational treatment for hereditary angioedema (HAE).

Business Wire 5 months ago

KALV
-2.58%
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

CAMBRIDGE, Mass. & SALISBURY, England, November 26, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company’s Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success.

Business Wire 5 months ago

KALV
-2.58%
KalVista Secures $184M Financing for Sebetralstat Launch

KalVista Pharmaceuticals ( (KALV) ) has provided an update. KalVista Pharmaceuticals has secured a significant up to $184 million synthetic royalty financing deal with DRI Healthcare Trust to fund the commercialization of sebetralstat, a novel oral therapy for hereditary angioedema (HAE). The agreement includes an initial $100 million upfront payment, potential milestone payments, and a tiered royalty structure based on global net sales. This strategic move strengthens KalVista’s financial posit

TipRanks 6 months ago

KALV
-2.58%

Performance Overview

Return	KALV	S&P 500 (^GSPC)
YTD	+33.88%	+0.19%
1-Year	-9.21%	+12.31%
3-Year	+16.79%	+46.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

KalVista Pharmaceuticals, Inc. (KALV)

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

KalVista licenses commercialisation rights for HAE to Kaken in Japan

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

Sector Update: Health Care Stocks Advance in Afternoon Trading

KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says

KalVista Appoints Jeb Ledell as Chief Operating Officer

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

KalVista Secures $184M Financing for Sebetralstat Launch

Performance Overview